Pharmagreen Extends the Letter of Intent Timeline with Advanced Bio-Oil Technologies Ltd.
April 19 2021 - 7:19AM
InvestorsHub NewsWire
CARSON CITY, NV -- April 19, 2021 -- InvestorsHub NewsWire --
Pharmagreen Biotech, Inc., (OTC
PINKS: PHBI), announces that the signed letter of intent with
Advanced Bio-oil Technologies Ltd. (ABOT), based in Denver,
Colorado, as announced on February 16, 2021 has been extended by
mutual agreement between the parties to June 30, 2021.
Pharmagreen to date has identified a number of opportunities for
acquisition and further development of the assets for tissue
culture starter plantlet production, extraction and product
formulation. As stated in February 16, 2021 news release,
Pharmagreen will provide the raw, crude Cannabiniod oils, grown by
its network of local hemp farmers and the Cannabiniod product
formulations will be developed as a joint venture with ABOT,
Advanced Bio-Oil Technologies Ltd. The LOI extension provides
Pharmagreen with the opportunity to more thoroughly investigate the
large number of site prospects and to secure the necessary funding
to secure the selected real estate assets.
Commenting on Pharmagreen’s progress, Peter Wojcik, President
and CEO, stated, “We are moving ahead as planned with our financing
plans for acquisition and biotech complex development. We look
forward to providing regular updates as we progress.”
ABOUT Advanced Bio-Oil Technologies Ltd. (ABOT)
Advanced Bio-Oil Technologies Limited (ABOT) is providing the
various industries a platform to produce Bio-Oil at-will. ABOT is
using biodegradable carbon molecule and innovative oil extraction
methods in its process. This extraction method would be used to
produce products for the bioenergy industry, the cosmetic or the
pharmaceutical. This process is producing better Bio-Oils. ABOT is
pleased to have collaborations with various groups in Uzbekistan,
Greece, Canada and USA. ABOT’s platform for producing high-grade
CBD Medical Bio-Oil will range from skincare products to specific
medical targets. Our products which will contain Hemp derived CBD
which will be marketed in North & South America and Europe.
About Pharmagreen Biotech, Inc.
Pharmagreen Biotech, Inc., is a publicly traded (OTC
PINKS: PHBI) company. Pharmagreen is a company focused on
the CBD hemp industry for the production and supply of starter
plantlets through a proprietary tissue culture process with the
opportunity to become one of the largest players globally.
Pharmagreens’ mission is to advance the technology of tissue
culture science and to provide the highest quality 100% germ free,
disease free and all genetically the same plantlets to CBD hemp
farmers and other flora while offering full spectrum DNA testing
for plant identification, live genetics preservation using tissue
cultures in low temperature storage for all plant species;
extraction of botanical oils mainly CBD oil, and to deliver
laboratory based services to the North American Cannabis and
agriculture sectors. For further information on the company
please visit www.pharmagreen.ca
Safe Harbor Statement
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause the Company's actual
results to differ materially from those projected in such
forward-looking statements. In particular, factors that could cause
actual results to differ materially from those in forward looking
statements include: our inability to obtain additional financing on
acceptable terms; risk that our products and services will not gain
widespread market acceptance; inability to compete with others who
provide comparable products; the failure of our technology; the
infringement of our technology with proprietary rights of third
parties; inability to respond to consumer demands; inability to
replace significant customers; seasonal nature of our business.
Forward-looking statements speak only as of the date made and are
not guarantees of future performance. We undertake no obligation to
publicly update or revise any forward-looking statements. When used
in this document, the words "believe," "expect," "anticipate,"
"estimate," "project," "plan," "should," "intend," "may," "will,"
"would," "potential," and similar expressions may be used to
identify forward-looking statements.
The OTC Markets or any other securities regulatory authority has
not reviewed and does not accept responsibility for the adequacy or
accuracy of this press release that has been prepared by
management
Contact Information: www.pharmagreen.ca
Tel: (702) 803 9404
Email: info@pharmagreen.ca
Pharmagreen Biotech (PK) (USOTC:PHBI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Pharmagreen Biotech (PK) (USOTC:PHBI)
Historical Stock Chart
From Jan 2024 to Jan 2025